In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).

Androgen deprivation therapies for metastatic prostate cancer are useful initially, but progression to androgen independence usually results in relapse within 2 years. The molecular mechanisms underlying the clinically important transition from androgen dependence to androgen independence are poorly described. Several lines of investigation have suggested that insulin-like growth factors (IGFs) are involved in the biology of prostate cancer, but little is known about their relevance to progression to androgen independence. We used three in vivo models of androgen-dependent (AD) human prostate cancer to study this issue. Progression to androgen-independent (AI) growth was associated with a 60-fold increase in expression of IGF-I mRNA in LAPC-9 xenografts and a 28-fold increase in IGF-I expression in LNCAP xenografts, relative to the initial AD neoplasms. IGF type I receptor (IGF-IR) mRNA levels were approximately 2.5-fold and approximately 5-fold higher, respectively, in AI LAPC-9 and LNCaP tumors compared with the original AD neoplasms. AI growth of these xenografts was also associated with significant reductions in IGF binding protein-3 expression. LAPC-4 xenografts, which previously have been shown to exhibit molecular pathology related to HER-2/neu expression with progression to AI, showed relatively minor changes in expression of the genes investigated, but we nevertheless found evidence of increased IGF-IR phosphorylation with progression to androgen independence in this model. Taken together with prior observations, our results suggest that deregulation of expression of genes related to any one of several critical receptor tyrosine kinase regulatory systems, including IGF signaling, may confer androgen independence.

[1]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[2]  S. Plymate,et al.  Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. , 2001, Endocrinology.

[3]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[4]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[5]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[6]  W. Cavenee,et al.  IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation , 2000, Oncogene.

[7]  J. Jorcano,et al.  Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Mantzoros,et al.  Hormonal predictors of prostate cancer: a meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Bowen,et al.  Differential IGF‐independent effects of insulin‐like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells , 1999, Journal of cellular biochemistry.

[10]  M. Pollak,et al.  Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. , 1999, Urology.

[11]  V. Hwa,et al.  The Insulin-like Growth Factor-binding Protein (igfbp) Superfamily* , 2022 .

[12]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[13]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[14]  M. Gleave,et al.  Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. , 1999, Cancer research.

[15]  M. Gleave,et al.  Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. , 1999, Cancer research.

[16]  J. Winer,et al.  Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. , 1999, Analytical biochemistry.

[17]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[18]  G Bartsch,et al.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.

[19]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[21]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Huynh,et al.  Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. , 1998, Endocrinology.

[23]  H. Huynh,et al.  Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. , 1997, Biochemical and biophysical research communications.

[24]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[25]  M. Gleave,et al.  A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. , 1997, Cancer research.

[26]  S. Plymate,et al.  Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. , 1997, Endocrinology.

[27]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[28]  D. Clemmons.  Insulin-like growth factor binding proteins and their role in controlling IGF actions. , 1997, Cytokine & growth factor reviews.

[29]  J. Thrasher,et al.  The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. , 1996, The Journal of clinical endocrinology and metabolism.

[30]  J. Ilan,et al.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Philip R. Cohen,et al.  The role of insulin-like growth factors in prostate biology. , 1996, Journal of andrology.

[32]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[33]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[34]  R. Rosenfeld,et al.  Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. , 1993, The Journal of biological chemistry.

[35]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[36]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[38]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.